Product Description
DC-853 is a differentiated fast follower molecule of DC 806 with improved potency and metabolic stability to support projected therapeutic benefit at lower doses DC-853 entering GLP safety studies; Phase 1 trials results anticipated 2023. (Sourced from: https://sec.report/Document/0001193125-22-044809/)
Mechanisms of Action: IL17 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Canada, Czech Republic, Germany, Hungary, Japan, Poland, United Kingdom, United States
Active Clinical Trial Count: 9
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Psoriasis
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
jRCT2031240450 |
jRCT2031240450 | P2 |
Not yet recruiting |
Psoriasis |
2025-12-31 |
|||
NCT06627088 |
J5C-MC-FOAE | P1 |
Completed |
Healthy Volunteers |
2024-12-31 |
50% |
2025-01-25 |
Primary Endpoints |
NCT06503679 |
J5C-MC-FOAF, DC-853104 | P1 |
Completed |
Healthy Volunteers |
2024-12-31 |
12% |
2025-01-25 |
Patient Enrollment|Primary Endpoints|Start Date|Treatments|Trial Status |
NCT06311656 |
DCE853107 | P1 |
Completed |
Healthy Volunteers |
2024-10-04 |
50% |
2025-02-26 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06345794 |
DCE853103 | P1 |
Completed |
Healthy Volunteers |
2024-06-18 |
50% |
2025-04-30 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT06937411 |
J5C-MC-FOAD | P1 |
Completed |
Healthy Volunteers |
2023-10-30 |
2025-04-23 |
Primary Endpoints|Treatments |
|
2024-512207-39-00 |
J5C-MC-FOAB | P2 |
Active, not recruiting |
Psoriasis |
2025-11-01 |
2025-05-02 |
Treatments |
|
NCT06916143 |
J5C-MC-FOAH, DCE853105 | P1 |
Recruiting |
Healthy Volunteers |
2026-01-01 |
88% |
2025-10-02 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06602219 |
J5C-MC-FOAB | P2 |
Completed |
Psoriasis |
2025-07-24 |
12% |
2025-09-13 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Trial Status |